Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Comment by InvestLargeCon Jul 12, 2017 10:23am
209 Views
Post# 26459455

RE:Implications for Evenergy - PLX deal at C$0.48

RE:Implications for Evenergy - PLX deal at C$0.48
stockfy wrote: it has passed unnoticed but Evenergy, the Chinese company that bought PLX at C$0.48, is not just another investor. Evenergy is a big player in the Chinese energy market with ample liquidity and we all know that the Chinese investors love investing in the Canadian energy sector, so this fact has multiple positive implications for PLX such as a buyout at a later time with a significant premium, additional cash injection at a later time if needed etc.

it has also passed unnoticed that Evenergy chose PLX among all the Canadian energy producers, which means that the Chinese investors realize the company's absurd undervaluation and significant upside potential. They realize that PLX's upside potential is significantly higher than those of the other Canadian energy producers. They are in PLX to maximize their ROIs, they are not in PLX just because they wanted to own a Canadian energy producer.

About Evenergy

Evenergy is a long term strategic investor targeting high quality oil and gas assets. Evenergy is a Hong Kong registered company, a subsidiary of Zhongcheng Group, one of the largest privately owned independent petroleum refinery, oil products and LPG distribution and retail companies in China.

 

Point Loma Resources Announces Investment Agreement with Evenergy Company Limited for proceeds of $4,020,000

CALGARY, AB--(Marketwired - May 24, 2017) - Point Loma Resources Ltd. (TSX VENTURE: PLX) (the "Corporation" or "Point Loma") is pleased to announce an investment agreement with Evenergy Company Limited ("Evenergy") for Evenergy to acquire 8,375,000 common shares of Point Loma for $4,020,000 representing a purchase price of $0.48 per share (the "Investment").

 



Is this company?

https://www.zocengroup.com/page.php?id=1

<< Previous
Bullboard Posts
Next >>